BridgeMD
New treatment option for Radioembolization
Official title Scout Dose of Resin Microspheres
ClinicalTrials.gov ID: NCT07476651
What this study is testing
- What it's testing
- This study looks at a liver cancer treatment called radioembolization and tests a new, possibly more accurate way to check if the treatment is safe for a patient's lungs. Radioembolization is a procedure where tiny beads containing a radioactive substance (yttrium-90) are injected into the arteries that feed a liver tumor.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Adults aged 19 years or older
- Hepatocellular carcinoma diagnosed radiologically according to the American Association for the Study of Liver Disease diagnostic criteria or...
- Volume of liver not included in the treatment field is at least 30% of the total non-tumorous liver volume
- Child-Pugh class A
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 ⑥ Patients with lung shunt fraction ≤20% on MAA scan (planar image) ⑦ Patients with...
You likely can't join if
- Patients with biliary-enteric anastomosis or biliary stent
- Cases where the operator judges that even mild radiation pneumonitis could be fatal due to findings of emphysema or interstitial lung disease on...
- Patients with a history of severe hypersensitivity reaction to iodinated contrast agents
- Patients with contraindications to angiography or catheter manipulation
- Patients with lung shunt fraction \>20% on MAA scan (planar image)
See the full eligibility criteria
- Adults aged 19 years or older
- Hepatocellular carcinoma diagnosed radiologically according to the American Association for the Study of Liver Disease diagnostic criteria or diagnosed histologically, histologically diagnosed intrahepatic...
- Volume of liver not included in the treatment field is at least 30% of the total non-tumorous liver volume
- Child-Pugh class A
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 ⑥ Patients with lung shunt fraction ≤20% on MAA scan (planar image) ⑦ Patients with no major organ abnormalities on blood tests performed within 2 months...
- A. Leukocytes ≥ 1,000/µL and ≤ 20,000/µL
- B. Hemoglobin ≥ 6.0 g/dL (transfusion allowed to meet this criterion)
- C. Total bilirubin ≤ 2.0 mg/dL
- D. Platelet ≥ 40,000/µL
- E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants
- F. Aspartate transaminase (AST) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit)
- G. Alanine transaminase (ALT) ≤ 800 IU/L (i.e., ≤ 20X upper normal limit)
- H. Creatinine ≤ 2.5 mg/dL (no restriction for dialysis patients) ⑧ Patients with life expectancy of at least 3 months ⑨ For women of childbearing potential, those with negative serum pregnancy test ⑩ Patients who fully...
- Patients with biliary-enteric anastomosis or biliary stent
- Cases where the operator judges that even mild radiation pneumonitis could be fatal due to findings of emphysema or interstitial lung disease on chest CT
- Patients with a history of severe hypersensitivity reaction to iodinated contrast agents
- Patients with contraindications to angiography or catheter manipulation
- Patients with lung shunt fraction \>20% on MAA scan (planar image)
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.